This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 26238 results found since Jan 2013.
Anorectal malignant mucosal melanoma
Ghana Med J. 2022 Dec;56(4):331-335. doi: 10.4314/gmj.v56i4.12.ABSTRACTAnorectal mucosal melanoma (AMM) is a rare, aggressive malignancy. The symptoms of AMM mimic common benign conditions in the anus, such as haemorrhoids; hence diagnosis is often made late, a third of patients having metastasis at first presentation. Surgical resection remains the standard of treatment, and adjuvant therapy is varied, including immunotherapy, brachytherapy, and chemotherapy. The prognosis is poor, with a 5-year survival of 20%. A 65year old woman presented with a five-year history of symptoms suggestive of haemorrhoids and was diagnosed ...
Source: Ghana Medical Journal - August 14, 2023 Category: African Health Authors: Antoinette A Bediako-Bowan Hafisatu Gbadamosi Hannah N G Ayettey Philemon K Kumassah Nicholas Aperkor Selorm Dake Uduak-Abasi Una Joojo Nyamekye-Baidoo Jonathan C B Dakubo Source Type: research
Locoregional treatment in patients with metastatic cervical cancer: benefit of dose escalation strategies
To examine the benefit of an intensive locoregional treatment including an image-guided adaptive brachytherapy (IGABT) among cervical cancer patients with extrapelvic extension.
Source: International Journal of Radiation Oncology * Biology * Physics - August 13, 2023 Category: Radiology Authors: A. Laville, K. Ka, R. El-Ayachi, S. Achkar, S. Bockel, S. Gouy, S. Espenel, P. Morice, R. Sun, P. Pautier, C. Chargari Tags: Clinical Investigation Source Type: research
Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis
This study was performed to evaluate the efficacy and safety of the combination therapy comprising transarterial chemoembolization (TACE), lenvatinib (L), programmed death-1 inhibitor (P), and iodine-125 seed (I125) brachytherapy relative to TACE in combination with lenvatinib plus programmed death-1 inhibitor therapy and TACE plus lenvatinib therapy.
Source: Brachytherapy - August 11, 2023 Category: Cancer & Oncology Authors: Long-Wang Lin, Le-Ye Yan, Kun Ke, Wei-Zhu Yang, Jun-Qing Lin, Ning Huang Source Type: research
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer
Treatment of locally advanced cervical cancer patients includes chemoradiation followed by brachytherapy. Our aim is to develop a delta radiomics (DRF) model from MRI-based brachytherapy treatment and assess its association with progression free survival (PFS).
Source: Brachytherapy - August 11, 2023 Category: Cancer & Oncology Authors: Christina Small, Phillip Prior, Haidy Nasief, Ross Zeitlin, Hina Saeed, Eric Paulson, Natalya Morrow, Jason Rownd, Beth Erickson, Meena Bedi Source Type: research
Global research status and hotspots of radiotherapy for prostate cancer: a bibliometric analysis based on Web of Science from 2010-2022
ConclusionThe application of RT targeting oligometastatic prostate cancer(OMPC) has garnered considerable attention among researchers. SBRT and BT have become hot topics in the field. Additionally, the BCR of PCa has long been a critical issue requiring extensive research and resolution, and salvage radiotherapy has currently emerged as a closely related research focus. Related large-scale multicenter studies have been conducted over the past few years, providing valuable insights. More high-quality research is expected to be employed to guide clinical decision-making.
Source: Frontiers in Oncology - August 11, 2023 Category: Cancer & Oncology Source Type: research
KORTUC, a novel hydrogen peroxide ‑based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer
Oncol Lett. 2023 Jul 20;26(3):378. doi: 10.3892/ol.2023.13964. eCollection 2023 Sep.ABSTRACTKochi Oxydol Radiation Therapy for Unresectable Carcinoma (KORTUC) is a novel radiosensitizer invented by Professor Ogawa at Kochi University (Japan) in 2006. The current study aimed to report the experience of the present authors with the use of KORTUC treatment in combination with interstitial brachytherapy (ISBT), with or without external beam (EB) radiotherapy (RT), in patients with locally recurrent cervical cancer (LRCC), who were likely to have a high risk of poor prognosis. Between April 2012 and January 2020, 14 female pati...
Source: Oncology Letters - August 10, 2023 Category: Cancer & Oncology Authors: Taiju Shimbo Ken Yoshida Mio Nakata Kazuma Kobata Takashi Ogawa Ayaka Kihara Chikara Sato Akihiro Hori Satoshi Takeno Hiroto Yoshioka Hironori Akiyama Keiji Nihei Source Type: research
Cancers, Vol. 15, Pages 4048: Prognostic Factors for Resolution Delay of Lower Urinary Tract Symptoms in Patients with Prostate Cancer after Low-Dose-Rate Brachytherapy
This study aimed to evaluate the chronological changes in the overactive bladder symptom score (OABSS) and the time-to-resolution of OABSS in patients undergoing LDR-BT. Patients with prostate cancer who underwent LDR-BT at Gifu University Hospital were enrolled. The OABSS was evaluated before and after LDR-BT. Patients were divided into the OABSS resolution and resolution delay groups, and the association between OABSS resolution delay and clinicopathological covariates was evaluated. In total, 237 patients were enrolled in this study, with a median follow-up of 88.3 months. The OABSS in both groups worsened at 3 months f...
Source: Cancers - August 10, 2023 Category: Cancer & Oncology Authors: Tomoki Taniguchi Makoto Kawase Keita Nakane Masahiro Nakano Koji Iinuma Daiki Kato Manabu Takai Yuki Tobisawa Takayuki Mori Hirota Takano Tomoyasu Kumano Masayuki Matsuo Takayasu Ito Takuya Koie Tags: Article Source Type: research
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Conditions: Hepatocellular Carcinoma; Hepatic Portal Vein Tumor Invasion; Tumor Thrombus Interventions: Procedure: I-125 Seeds Brachytherapy in PVTT; Procedure: Transcatheter arterial chemoembolization; Drug: Atezolizumab plus Bevacizumab Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Sun Yat-sen University; Second Affiliated Hospital of Guangzhou Medical University; Fifth Affiliated Hospital, Sun Yat-Sen University; Maoming People's Hospital; Shandong Provincial Third Hospital Not yet recruiting
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
